Medicus Pharma Ltd. entered into a non‑binding letter of intent with Reliant AI Inc. on December 22, 2025 to develop an artificial‑intelligence‑powered data analytics platform for its clinical programs.
The partnership will focus initially on dynamic site selection and patient stratification for the Teverelix prostate‑cancer study that is slated to begin in 2026. The LOI is non‑binding and the initial engagement is capped at $200,000 over 12 months, with future milestones tied to performance and integration progress.
The collaboration is a strategic step for Medicus, which reported $8.7 million in cash and cash equivalents at the end of Q3 2025, up from $5.3 million a year earlier, and a net loss of $15.98 million. Operating expenses for the quarter were $15.4 million, a sharp increase from $2.3 million in the same period a year earlier. The AI platform is expected to reduce trial costs and accelerate timelines, helping the company meet its 2026 milestones before its limited cash runway expires.
Medicus’s pipeline includes the Teverelix program, acquired in August 2025 through the purchase of UK‑based Antev Ltd., and the SkinJect microneedle therapy for basal cell carcinoma, for which Phase 2 enrollment has been completed and topline results are expected in Q1 2026.
Dr. Raza Bokhari, Executive Chairman and CEO, said the partnership “reflects an important strategic step of selectively deploying advanced analytics and AI tools to improve the efficiency, quality, and predictability of clinical development.”
Reliant AI, founded by former DeepMind and Google Brain researchers, brings a strong technical foundation to the collaboration, positioning Medicus to gain a competitive edge in clinical trial optimization.
The LOI represents a key milestone for Medicus as it seeks to advance its pipeline efficiently while managing a tight cash position, underscoring the importance of the partnership for the company’s near‑term execution and long‑term viability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.